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ABSTRACT 
Human induced pluripotent (iPS) cells offer a theoretically inexhaustible cell source for the 
derivation of any cell type and are a promising tool in regenerative medicine. Cells can be 
derived from the recipients own tissue or from pre-selected HLA-matched donors. Certain 
disease relevant cell types derived from iPS cells can be cryopreserved, distributed world-
wide and made available on demand. These factors taken together indicates iPS cells could 
potentially revolutionize medicine.  
 
Technological maturation has been fast paced with rapid advances in derivation and culture 
techniques in the last decade, creating cells of sufficient quality to motivate in human use. 
The first clinical trials performed with iPS cell derived grafts have so far been conducted 
without indications of adverse events. Pioneering applications are now being evaluated in 
humans. Meanwhile, academia and industry alike are taking strides to industrialize cell 
manufacture in anticipation of commercial applications. Strategies utilizing genome editing 
are opening up entirely new venues for future applications. 
 
However, challenges does not solely lay in developing efficacious cell therapies. Pioneering 
cell therapy products have so far been exceptionally costly. Finding strategies minimize cost 
may be as an important as proving efficacy if  any novel cell therapies are ever going to 
benefit society. 
 
Regulations dictating the use of iPS cell derived cell therapies remains unspecific yet 
demanding and insufficiently harmonized internationally. Efforts are ongoing to coordinate 
in-between regulatory authorities and more defined criteria for manufacture and regulatory 
approval is slowly emerging. 
 
It has now been little over 10 years since the derivation of the first human iPS cell lines. A 
decade which has seen many barriers overcome. The upcoming decade is likely to be even 
more exciting and challenging, as therapies will need, not only to be consistently proven safe, 
but also efficacious and commercially viable.   
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1 REGENERATIVE MEDICINE 
1.1 REGENERATIVE MEDICINE THROUGH THE AGES 
 
The field of regenerative medicine can seem like science fiction. The fundamental concept 
behind it is to repair, replace or regenerate cells, organs or tissues to restore functions4. 
Certain tissues of the adult human body are only capable of very limited tissue regeneration. 
This is in stark contrast to early development were totipotent and pluripotent stem cells has 
the potential to proliferate and differentiate into all tissues that make up the body. A loss of 
stemness occur as cells differentiate and specialize. If adult cells could be reverted to earlier 
developmental stage, the regenerative potential of stem cells could be unleashed to repair 
damages injuries the adult physiology are unable to handle.  
 
Stem cell therapy is not an entirely novel concept, transplantations of adult hematopoietic 
stem cells derived from bone marrow has been in clinical use since the 1960s. Rapid 
developments in the field in the 1990s enabled the culture and derivation of multiple new 
stem cell types with therapeutic potential5. Transplantation of adult stem-cells-like 
mesenchymal stem cells was first clinically evaluated in 19956, although transplantation of 
these cells are being considered in a broad spectrum of condition today, the limited 
differentiation potential of adult stem cells constrain their regenerative abilities7. 
Transplantations trails using fetal-derived progenitor cells was pioneered with mixed results 
in Parkinson’s disease, age related macular degeneration, spinal cord injury and heart failure, 
to mention a few8-10. These studies have come to serve as proof-of-concept in regenerative 
medicine but the limited quantity, and quality of fetal tissue available meant that large-scale 
therapies are not feasible11. 
 
1.2 PLURIPOTENT STEM CELLS 
 
The capture of the first human embryonic stem (ES) cell line was in 199812 drastically 
widened the potential of cell therapies bringing with it a vision of seemingly limitless 
potential. ES cells are able to generating any tissue of the adult human body on theoretically 
limitless scale12. Several ES cell-derived therapies have since progressed to clinical trials13. 
However, the use of ES cells has and is still the topic of harsh debate. Ethical concerns mainly 
focusing on the origin the of ES cells. Pluripotent cells can also be derived by somatic cell 
nuclear transfer (SCNT) but is technically complicated14 and also raises ethical dilemmas 
concerning the destruction of viable human embryos15. Pathogenic stem cells, chemically 
induced uniparental zygotes unable to develop into a viable embryo but with clonal self-
renewal capacity partly forgo those argumentations. Pathogenic stem cells display unique 
epigenetic imprinting which limits their linage specification ability and application16.  
 
A breakthrough came in 2006 with the advent of a new type of human pluripotent cell type, 
the so called induced pluripotent stem (iPS) cells. These cells circumvent the ethical and legal 
concerns of ES cells altogether. The discovery was made by a team of Japanese scientists 
exploring the possibility to reactivate the pluripotency transcriptional pathways in adult 
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somatic cells and by doing so creating an artificial embryonic like stem cell17. Effectively 
turning back the developmental machinery of adult cell to a stage a few days after 
fertilization.  
1.3 THE REPROGRAMMING PROCESS  
1.3.1 Reversing the Order of Development Determined by 3,5 Billion Years of 
Evolution 
 
Genes code for protein, proteins shape life in the form of cells and cells form complex 
organisms that procreate, age and die. The cycle of life, constantly moving in a determined 
direction obeying the laws written and formed by small forces acting over uncomprehensive 
long times. The rules are ancient, but science has previously enabled us to break such laws 
of nature. 
 
Our genes are inherited through our DNA which serves as a blueprint, coding mostly for 
protein production. Proteins is the incredibly versatile molecules of life, tools through which 
our cells form incredibly diverse tissues. Proteins are differently expressed in different 
tissues, giving rise to a plethora of different cell types in our bodies. Either selective loss of 
DNA occurs during development or intricate processes, invisible to the naked eye, 
irreversibly control how genes are expressed.  
 
Decades before the molecular structure of our DNA had been determined it was proposed 
that the presence of certain genes alone might not be solely responsible for the functions of 
an organism and hence the field of 
epigenetics was born18. The hypothesized 
elements of epigenetics were working on a 
step above the genome, modulating the 
expression and thereby allowing the 
functions of cells to diverge. The process was 
conceptualized by Waddington et al.1 as a 
marble rolling down a hill getting caught in 
valleys as it irreversibly rolls down the hill of 
development but never up (Figure 1)1. At the 
summit of this model, is the zygote, the first 
cell of any individual, imbued with the 
potential to create entire organisms in all their 
diversity. Each intersection, represent a fate-
choice and a restriction in the potency of the marble. 
 
Cancers gave some indication that it was perhaps possible to partly change the predetermined 
fate of cells but it was not until John Gurdon pioneered his landmark experiments on SCNT 
that the irreversibility of cellular differentiation by experimental means was disproven. The 
nuclei from an oocyte from a tadpole (Rana pipiens) was replaced with an intestinal epithelial 
cell nuclei resulting in the development and birth of an new individual. This experiment 
suggested that even mature cells retain the complete genetic information suggesting that 
Figure 1. Epigenetic landscape proposed by            
Waddington et al.1 Adapted from S.Bhattacharya et al. 
20113 
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certain factors excise firm control of gene expression and thereby dictating cell state.15, 19, 20. 
This concept was proven similarly in mammals in 1996 with the birth of Dolly the sheep21. 
1.3.2 To Master the Genome 
 
The knowledge that even adult cell retains a full genome and uncovering the prospect of 
reverting adult cells to earlier developmental origins had an enormous implication for 
medicine. If the epigenetics could be controlled, tissues otherwise incapable of regeneration 
could be reverted to an earlier stage of development were cells were potent to form the tissue. 
The epigenome operates is on several levels, through diverse actions, acting both pre- and 
post-transcriptionally. Mechanisms include control of chromatin state, DNA methylation and 
non-coding RNAs22 A stride towards controlling cell fate was taking in 1987 when the 
programing of fibroblast cells into myoblasts by introducing specific genes via retroviral 
vectors, later known as transcriptions factors23. Specific combinations of transcription factors 
regulate batteries of genes which determine and maintain cell fate24. The knowledge that 
transcription factors held the potential to influence fate-switching in cells, encouraged the 
study of transcription factors particularly expressed in oocytes and ES cell maintenance. It 
was by doing this, Yamanaka et. al managed cell reprogramming by a defined set of 
ectopically expressed reprogramming factors. Out of many, four factors were identified as 
sufficient to reverse the otherwise irreversible flow of time17. Although other factor 
combinations has since proven possible25 the Yamanaka factors remain in use to this day26.  
1.3.3 Mechanisms of Reprograming 
 
The mechanisms of reprogramming using the Yamanaka factors OCT4, KLF4, SOX2 and c-
MYC (OKSM) has been described to occur in two transcriptional waves27.  First, a stochastic 
wave, were c-MYC is thought to be responsible for repression of somatic genes and 
upregulation of proliferation. KLF4 also indicated to play a role in the repression of somatic 
factors in this early state. Typical for the early stage of the reprogramming process is 
dedifferentiation, increase in proliferation, loss of somatic gene expression, and upregulation 
of proliferation associated genes. The effects are highly heterogenous on the cells and only a 
few will actually proceed to the second stage28. The second wave of transcriptional activity 
follow a more deterministic sequence of events which is dependent on OCT4, SOX2 and 
KLF4 triggering the expression of the pluripotency genes28, 29. Only a rare few cells will 
successfully pass through these sequences of events and manage to switch on and 
endogenously maintain the pluripotency circuitry28. Regardless of the factors used for 
reprogramming the end result is similar. This indicates that the factors used for reprograming 
either serve similar functions in reprogramming or trigger transcription of a series of other 
factors essential for pluripotency30.   
 
The process of reprograming described above deviates from that observed in SCNT which is 
rapid and more deterministic, also in the early phase31. The more controlled environment and 
reprogramming factors at physiological levels in the oocyte is thought to contribute. This 
indicates that current reprogramming schemes could potentially yet be improved.   
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1.3.4 A Golden Standard for Perfecting Reprogramming 
 
Perhaps not all iPS cells are created equal. Fortunately, there are pluripotent stem cells from 
embryonic sources which long has served as a golden standard. ES cells are derived from the 
inner cell mass of the blastocyst around day 5-6 after fertilization12. The cells that are destined 
to become iPS cells go far beyond the day 5-6 days, and are derived from post-natal tissue, 
possibly after several decades of life before being reprogrammed back an ES-like state. A 
question that has preoccupied the field for years is if this difference in cell source is reflected 
in meaningful functional differences.  
1.3.5 Epigenetic Memory 
 
Beyond the apparent similarity in form and function between ES and iPS cells, early reports 
indicated small but potentially significant differences observed in-between ES cells and iPS. 
Slight differences in gene expression profiles32, differences in methylation patterns 33 and 
epigenetic memory retained from tissue of origin34 was reported. The epigenetic memory was 
indicated to give preferential differentiation into tissue types remising of cell type origin35 
however this epigenetic memory could be lost with modest passaging of iPS cells34. With as 
little as ten passages the epigenetic memory was near eliminated and with sixteen passages 
cells were indistinguishable based on origin35. Later studies comparing isogenic iPS cells 
derived from different tissue sources found that the variation in differentiation propensity is 
rather due to donor dependent variations in expression and methylation rather than from the 
tissue of origin36, 37. 
 
A recent study of over 700 iPS cell lines from 301 donors identified the donor as the biggest 
source of variance, accounting for 46% of variation, 23% was attributed copy number 
variations, 26% ascribed to culture condition, 2% to passage number and 2% gender38. 
Although most but not all iPS cell lines can be distinguished from ES cell lines based on 
variability in transcription, the individual difference between any pluripotent lines is larger 
than variability in-between ES cells and iPS cells39. It may therefore be reasonable to put 
more focus on the variability in-between cell lines rather than the source of the pluripotent 
stem cells36, 37, 39-41.  
1.3.6 Differentiation Bias 
 
Pluripotent stem (PS) cells are theoretically capable of deriving most cell types if not all, 
however they do display potential bias towards certain germ layers42. This does not mean 
certain lines cannot differentiate into certain cell types, but certain lines may do so at lower 
efficiencies. The differences is due to discrete variations in DNA methylation patterns and 
gene expression levels in-between cell lines, which is a phenomenon observed in both ES 
and iPS cell lines43. As we have discussed this differences is primary donor dependent rather 
than occurring from tissue of origin36 but remain stable over passages44. Assays has been 
developed to predict the differentiation bias towards germ layers43.  
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1.3.7 Different States of Pluripotency 
 
Perplexing differences was observed in-between mouse ES cells45, 46 and human ES cells12. 
Although both cell types are derived from cells of the blastocyst, key differences could not 
be ignored and the possibility of multiple pluripotent states was proposed47 Mouse PS cells 
grow in dome like shapes, female cells have two active X chromosomes and maintenance of 
pluripotency depend on LIF and BMP signaling instead of FGF/Activin in human pluripotent 
cells48. The capture of human Naïve pluripotent stem cells was reported in 2013 and provided 
a pluripotent state in humans resembling that observed in mice49. Naïve pluripotent cells have 
a higher degree of clonogenicity, higher proliferation rates, low degree of differentiation bias 
and are more permissive to genome editing50-52. In this text, the first discovered state, the 
primed state is discussed unless otherwise stated. 
 
Naïve cells probably closest resemble the cells of the preimplantation epiblast53 similar to 
those from day 6-7 post fertilization while primed cells more likely resemble  day 9-12 in the 
post implantation period (Figure 2). Determining the precise developmental equivalent is 
hindered by ethical considerations against studying human embryos48.  The derivation of 
primordial germ cells is much higher with Naïve cells but seems at best very limited by 
primed pluripotent stem cells54. Naïve cells also allow the study of certain features of the 
preimplantation embryo53. With the right culture condition, primed cells can be reverted to a 
naïve state and vice versa without the use of transgenes.55 Both conversion protocols and 
direct to naïve reprogramming have so far depended on culture on mouse embryonic 
fibroblasts (MEF)51, 53, 56.  Although Naïve cells display more homogeneous differentiation 
to germ layers then primed cell lines their ability to differentiate to terminal functional cell 
types seems limited56, 57 this in combined with the xenogeneic derivation is currently 
hampering their utility for regenerative medicine protocols56. However, one recent study 
have reported mature differentiation of cell types from naïve cells with adapted protocols51. 
 
The possibility of even further pluripotent states has been reported. Extended pluripotent 
stem cells with a propensity to also differentiate into extraembryonic tissues58. The derivation 
of these cells is somewhat controversial53 since they more closely adhere to the definition of 
totipotency. However, their lack of autonomous developmental potential place them in a gray 
zone between totipotent and pluripotent.  
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Figure 2. Early human development and derivation of pluripotent and fetal cells. The fusion of oocyte and spermatozoa 
result in the totipotent zygote. Both Naïve and primed ES cells are derived from the inner cell mass of the pre-implantation 
blastocyst. However, both most likely resemble later stages of development, Naïve around d6-7 and primed 9-12 days post 
fertilization. Fetal derived cells can be derived at later stages. Neuroepithelial stem (NES) are derived around Gestational 
week (GW) 5-7. Both Naïve and primed iPS cells can also be derived by reprogramming of adult tissues. Pluripotent stem 
cells can be differentiated to fetal cells such as NES cells. Their vast proliferative potential of pluripotent cells means 
theoretically unlimited amounts can be derived.  Naive pluripotent stem cells from Theunissen et al 201459, adapted from 
Uhlin, Marin Navarro et al, 20172. 
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2 MANUFACTURE OF INDUCED PLURIPOTENT STEM 
CELLS 
 
Since the derivation of the first human iPS cell lines in 2007 the progress in the field has been 
rapid25, 60. iPS cells has proven its worth in diverse fields with applications ranging from 
disease modelling61-63, drug discovery64 and regenerative medicine65. The use of iPS cells in 
the regenerative medicine has been lagging behind other applications, awaiting further 
developments in culture systems, vector technology, maturation of regulatory consistency 
and sufficient commercial interests to warrant financial feasibility of projects.  
 
At the time of writing, at least four clinical trials has transplanted iPS cell derived grafts, in 
macular degeneration13, 65, Parkinson’s disease66, graft vs host disease67 and cancer68. 
However, a torrent of novel phase I trials are schedule to commence imminently exploring 
treatments of spinal cord injury (SCI)69, Parkinson’s disease69, 70, diabetes and heart disease71. 
Trials using ES cell-derived tissues have progressed further with ongoing trials including 
SCI, diabetes type I72 and heart failure13, 73. 
 
The reason behind the sharp rise in planned iPS cell-derived cell therapies is not coincidental. 
Two important hurdles have been holding clinical translation back. The first obstacle is 
technological maturation, and the second is a legislative and increased understanding and 
acceptance with regulatory authorities. As regenerative therapies, PS cells derived tissues are 
neither recognized as solid organ transplants nor as pharmaceuticals. A novel legislative 
group of therapeutics had to be created to regulate these new era biological treatments, known 
as advanced therapy medicinal products (ATMPs)74. A tailored set of regulations, much more 
demanding to meet, has been set up, reflecting the complexity of the therapies.    
 
As it comes to technological hurdles PS cells has brought many innovative techniques to the 
table, iPS cells in particular. As mentioned previously, ES cell-derived therapies have 
progressed further, partly because ES cells was discovered almost a decade prior and partly 
because ES cells do not require reprogramming to reach a state of pluripotency. The cons of 
ES cells include the ethical datable source, the inherent difficulty in donor screening for 
Human leukocyte antigen (HLA)75 and the derivation of autologous transplants is not 
possible.  
 
Due to the rapid emergence of the field, many technologies required to derive cells are still 
covered by patents. Patents can be vital for projects to securing funding but can also can limit 
developments when rights to key technology is kept exclusive. Freedom to operate allows 
academic research but can block commercial projects such as ATMP development. Own 
experience indicates that some holders of intellectual property (IP) are more permissive than 
others when it comes to licensing their technology for commercial enterprise. Licensing the 
use of the Yamanaka factors from academia Japan has been obtain by some and similarly the 
use of  the Sendai vector technology. Reprogramming with certain mRNA kits is more 
complex. The more complicated IP landscape for iPS cell derivation, and the lower degree 
of IP protected technologies required for ES cell derivation, could, in the short term, favor 
the use of ES cells where legislation is permissive of their use. 
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2.1.1 Technologies for the Reprograming of Somatic Cells into iPS Cells 
 
The process of reprogramming has been of concern as it necessitates the introduction of genes 
supporting the limitless proliferation of cells. Transplantations of undifferentiated pluripotent 
stem cells into immunosuppressed animal models leads to teratoma formation12, 60. However, 
there is no therapeutically potential of directly injecting PS cells, the concern has been that 
the graft could harbor small subsets of undifferentiated PS cells76. In this case both ES and 
iPS cells are equal, but with iPS cells there is also the added apprehension regarding the 
reactivation of integrated vectors could lead to tumor formation77. Therefore, it is essential 
that the vectors used to deliver the reprogramming factors are transient in nature, footprint 
free and carry no risk of integration into the genome.  
 
This first iPS cell lines where derived by integrating retroviral vectors60. Retroviral vectors 
are associated with several issues, including, reactivation of pluripotency factors77, 
insertional mutagenesis25 and interference with the differentiation of iPS cells78. As the field 
evolved, so did the reprogramming methods available. A leap forward was taken with the 
introduction of reprogramming via episomal transfer vectors78. While this method offers 
transient expression of factors, the DNA based nature of this technique means the unintended 
integration of vectors by homologous recombination is possible. This has, as of yet, not 
disqualified therapies based on episomal vectors to spearhead iPS cell derived cell therapy 
developments. Although, tedious and costly screening for integration of reprogramming 
factors has been required before clinical use.65, 79 Also, cells require prolonged passaging in 
vitro to shed the vectors80. Prolonged iPS cell culture risk introducing and selecting for 
genetic and epigenetic abnormalities81-83. Derivation of lines using episomal vectors is further 
complicated by the very low reprogramming efficiency of about 0,0013%84.  
 
Development of RNA based non-integrating vector systems would eliminate the need to 
screen for transgene integration as vector integration through genomic recombination would 
not be possible85. Sendai viral vectors was introduced as an alternative, resulting in strong 
yet transient expression of factors without having a DNA-phase, deriving iPS with high 
efficiency of >1%86. Reprogramming vectors delivered by Sendai virus require extensive 
passaging to ensure shedding vectors (Figure 3)26.  
 
A new generation of mRNA based85, recombinant human protein87 and small molecule 
compounds88 offer more transient expression of factors and allow quicker derivation of lines, 
while reducing the extensive post-derivation safety testing. Difficulty has surrounded the 
development of these methods. Protein reprogramming technology remain costly and 
inefficient89 while small molecules has, to date, not been proven to work in humans90. Of 
these methods, only mRNA based reprogramming has developed to become an established 
form of reprogramming84. 
 
The strength of mRNA vectors is the highly transient nature of the system. Within 42 hours 
of vectors administration the exogenic protein levels have returned to baseline85. mRNA 
offers a footprint free method of reprogramming, abolishing the need to screen for transgene 
integration or for prolonged passaging, and eliminate the use of virus while offering a good 
efficiency. So far, use of mRNA reprogramming have been limited to adherent cell types, 
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such as fibroblasts, no account of reprogramming of peripheral blood mononuclear cells 
(PBMC) cells could be discovered.  The difficulty in transfecting PBMCs is because of high 
cytotoxic response to the mRNAs in the cell type91 Blood samples can still be used for 
reprogramming but depend on the establishment of endothelial progenitor cells91. 
 
 
2.1.2 Development of Clinically Relevant Cell Culture Systems  
 
The effect of the culture system on the cells cannot be overstated. A plethora of factors 
contribute to determining cell fates including, mechanical forces, cell contact 92 culture 
matrix, paracrine factors93, and the potential presence of cell subpopulations44, 94. Balancing 
these factors is fundamental to achieve the desired result. Replacing any culture component 
can lead to differences in the end products. Two recent studies showed preclinical failure of 
cell therapies when research grade components had been substituted for clinical reagents and 
manufacturing subjected to good manufacturing practice (GMP)95, 96. It is therefore essential 
to establish a robust clinically relevant protocol as early as possible as clinical adaptation 
often affect the cell product.  
 
With the imminent commencement of several of iPS cell based therapies clinical trials, 
demands put on the reproducibility, standardization of batches, and proof-of-safety are vital 
to address97. Ideally, cell culture systems aimed at clinical use should if possible exclude 
products of animal origin and where possible only use defined components98. A multitude of 
arguments have been put forward against of xenogeneic and undefined culture conditions 
including the risk of microbial contamination, variability of the final product and 
immunogenicity of derived cells99, 100. Transfer of non-human immunogenic siliac acids has 
been confirmed to occur from xenogeneic components to stem cells in culture101. 
 
Early culture systems were dependent on coculture with fibroblasts feeder cells layers12, 102 
or undefined matrixes such as Matrigel103 and culture with media often enriched by fetal 
Figure 3.  The isolation and reprogramming of human dermal fibroblasts. The timeline applies to Sendai viral vector 
reprogramming. Experiences from own lab  indicate mRNA reprogramming can shorten derivation by up to 5 weeks. 
Adapted from Uhlin, Marin Navarro et al, 20172. 
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bovine serum (FBS)12, 60. Batch-to-batch variability is associated with these components 
leading to variations in the final product100. Development of defined cell culture matrixes for 
instance Laminin-521104or vitronectin105 and the refinement of cell culture medias such as 
Essential 8106 allows for defined cultures with reduced variability and reproducibility of 
protocols. 
 
The implications for regulatory approval of cells derived using animal or undefined 
components for the production of cell for clinical use has so far been handled on a case to 
case basis by “risk-based approach”. The general notion is that if better alternatives are 
available those should be used. The inclusion of such components has carried with it strict 
demands of proving their use is safe and result in sufficient quality107 This often result in 
laborious work, or the development and implementations of various assays into the quality 
control regiment. In addition to these technical hurdles, the use of FBS and coculture with 
feeder cells provide major obstacles for the scale-up of production and thereby hindering the 
emergence of novel therapies108, 109. Taken together, xenogeneic and undefined components 
raise concern of variability and safety and should be excluded where possible. 
2.2 ESTABLISHMENT OF COHERENT REGULATION OF ATMPS  
 
With many of the technological hurdles considerably flattened by technological maturation, 
the establishment of internationally harmonized legislations is called for. Such legislation 
should be capable of safeguarding patient interests without smothering progress while 
allowing international approval of therapies. Today, there are no universal regulations in the 
field regarding ATMPs. Assessments are done by the individual regulatory authorities. 
However, there are ongoing efforts of harmonization in-between authorities, primarily the 
European medicines agency (EMA), the Food and drug administration (FDA), the Japanese 
and the Canadian authorities110. This text will focus on the regulations by the EMA, 
responsible for issuing market approval in the EU and the Swedish medicinal products 
agency, responsible for approval of clinical trials conducted in Sweden. The nearest thing to 
universal legislation available is the guidelines presented by the international society for stem 
cells research (ISSCR). The ISSCR regularly presents guidelines on stem cell research and 
clinical translation, commenting on preferred technical practices, but also ethical and policy 
changes as the field develops98.  
 
The international conference on harmonization of good clinical practice (ICH-GCP) was 
launched as an attempt by the regulatory authorities in European Union, United States and 
Japan to “provide a unified standard to facilitate the mutual acceptance of clinical data by the 
regulatory authorities in these jurisdictions”. According to these guidelines any 
investigational product must be produced under GMP111. Solid organ transplantations are not 
subordinate to these rules, however, PS cell-derived therapies are classified by the EMA as 
ATMPs which requires manufacturing under strict GMP74 The purpose of which is defined 
by both the EMA and the FDA as, the ability of manufacturing process to meet pre-set 
product criteria through control, donor testing, traceability, documentation of manufacturing 
and development and later the quality control of the product. The rules have been developed 
to safeguard consistent quality and guarantee the safety of the products in clinical use97. 
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Neither good clinical practice (GCP) nor GMP does forbid the use of animal or undefined 
products unless better options are available, but requires meticulous risk assessment for their 
inclusion112. The legislations are regularly updated and adjusted for recent developments and 
provide increasingly specific technical requirements and standards113. These legislations 
stress the importance that the safety of the product must be evaluated. The safety of PS cell 
derived products needs to be fully addressed and demonstrated by preclinical data including 
chromosomal stability, biodistribution, cell identity, sterility, mutations in oncogenes and 
housekeeping genes as well as genes involved with cell function. Currently, there is little 
agreement of what standards should be used or even how the data should be interpreted.71 
Clearer standards would facilitate developments and should be set on a multinational scale. 
2.2.1 Derivation of Clinically Relevant cGMP Compliant iPS Cell Lines  
 
The first pluripotent stem cells used to derive tissues for the first clinical trials were not up 
to the standards described above. Many of the lines were derived using xenogeneic 
substances, on feeder cells, in research grade facilities, with insufficient consent and then 
been subject for post- derivation classification as cGMP compliant by additional testing114. 
Such inverse qualification is unlikely to be recognized in the future since alternative 
derivation methods have since been developed.  
 
To date, only five groups have published the successful derivation of fully GMP compliant 
iPS cell lines79, 115-118 highlighting the apparent difficulty of such an endeavor (Table 1). Even 
so, the IPS cell line going into the clinics in the first ever trial65, was not manufactured under 
GMP but good laboratory practice (GLP), and subject to a series of exemptions allowing the 
ground-breaking use in humans, in a bid by the Japanese government to spearhead 
developments in regenerative medicine119, 120. Attempts to circumvent the regulations by 
converting research grade lines to GMP-grade by introducing them to a different culture 
system and meticulous quality control testing, deriving what is referred to as “putatively 
GMP compliant” has been suggested as a faster and less costly way to derive lines121. The 
GMP compliant cell lines published by Baghbaderani BA et al. by the efforts of the Lonza 
corporation published a protocol not fully living up to the goal of producing cells in a xeno-
free and defined manor, using both xenogeneic products and undefined components79. Wiley 
et al, were able to fully exclude xenogeneic products from their iPS reprogramming and 
maintenance process, however the authors highlight the dependency on human serum for the 
culture of fibroblasts as a drawback116, 122. Haase et al. recently published a fully xeno-free 
and defined derivation of cGMP compliant lines by sendai virus reprograming of 
hematopoietic stem cells from peripheral blood118, 123. Quite an achievement, however, 
substituting the sendai virus mediated reprogramming for a non-viral vector mRNA vectors 
could shorten production the production time and boost the clinical relevance even further85.  
The manufacture of GMP compliant lines are clear signs that the technical developments are 
approaching maturity. What remains now, is to ensure the use of GMP manufactured lines 
going forward and to derive cell therapy products of equal standard. 
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PS 
Cell 
type 
Author Xeno-
free 
Defined Starting 
material 
Reprogramming 
Vector 
GMP 
Compliance 
Year 
Published 
ES Thomson12 No No Embryo N/A No 1998 
iPS Kamao et al65, 
124 
No No Dermal 
Fibroblasts 
Episomal No 2014 
iPS Baghbaderani 
et al79 
No No Cord blood Episomal Yes 2015 
iPS Wang et 
al115* 
Yes No Foreskin 
fibroblasts 
Sendai Yes 2015 
iPS Wiley et al122 Yes No Foreskin 
fibroblasts 
Sendai Yes 2017 
iPS Haase et al118 Yes Yes Dermal 
fibroblasts 
Sendai Yes 2019 
 
 
 
2.2.2 Considerations for Development of Cell Therapies from Human Pluripotent 
Stem Cells  
 
To widen the perspectives, the objective is not solely to provide proof of concept but for the 
development of novel therapies to benefit the public. Academic scientists must consider the 
later stages of development or risk developing functioning therapies which can never be 
commercially viable and hence never reach the intended patients125. To successfully develop 
a cell therapy, it is necessary to adopt a backwards approach and consider three key points 
which are vital to address if a therapy is to have a chance of becoming successful. These are 
characterization, scale-up and cost of goods126.  
 
Characterization which is essential for safety, efficacy and to ensure comparability when the 
protocol is inevitable adjusted for scale up or when components are substituted. For scale up 
to be possible, it is important to minimize time consuming manual processes and choose 
culture system that allows to be expanded to larger size or translated into bioreactors. Every 
part of the chosen manufacturing process will be reflected in the cost of the final product. 
The most imperative to consider here is if the therapy can be allogenic or autologous, and if 
cryopreservation will be possible. Cryopreservation can vastly extend shelf life and enable 
storage and distribution of doses. The first in human trial for ES cells derived therapy and 
iPS cell therapy provide widely different approaches to some of these concepts.  
Table 1. Clinically relevant PS cells. The first ES cell line and the first iPS cell line used in clinics (top of the 
table), and four of the five published iPS cell lines derived under GMP compliance. Note, the ES cell line and the 
first iPS line to reach clinical use was not produce under GMP. *not necessary under the ICH definition of GMP. 
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2.2.3 The World’s First Pluripotent cell Derived Cell Therapy in Clinical Trials 
 
The Geron corporation developed the world’s first pluripotent cell derived cell therapy, 
consisting of oligodendrocyte progenitor cell therapy for subacute SCI and progressed to 
phase I clinical trials127. A total of five patients was grafted before a premature shutdown of 
the trail. According to all indications the trail progressed well with no indications of serious 
adverse events and termination was instead due to economic considerations128.  
 
The protocol used allogenic, cryopreserved doses of oligodendrocyte progenitor to which a 
thorough characterization protocol was applied. The thorough characterization accelerated 
the positive risk benefit assessment issued by the FDA contributing to the pioneering 
achievement several years ahead of its time.129 A very elegant set up which could with 
relative ease be scaled to meet future market demands and distributed. 
 
Many ethical and other criticism has rightfully been raised against the handling of the trail, 
choose of condition, patients and premature cancellation128. However, developments are still 
ongoing under Asterias that acquired Geron in 2012, and Phase I/IIa clinical trials with 25 
participants was resumed in 2014 and concluded in 2018130 with no serious adverse events 
reported and 95% of subjects reporting improved motor function131.  
 
A possible benefit with using progenitor cells is that they are not necessary disease specific, 
with a wide differentiation potential more diseases can be treated with the same drug product. 
Dopaminergic neurons are specific to Parkinson’s disease while OPCs, MSCs, NS cells or 
NES cells are not. Safety data can be used for other application of the same drug an facilitate 
cheaper and faster developments. OPCs could hypothetically also have uses in MS and white 
matter stroke131. 
2.2.4 iPS Derived RPE Tissue for Age Related Macular Degeneration 
 
If the protocol of the first ES cell trail can be described as elegant and scalable the opposite 
must be said for the first iPS cell trial were little considerations was taken. A tissue transplant 
of non-cryopreserveable Retinal pigment epithelium (RPE) cell sheet derived from patient 
specific autologous cells as a therapy for age related macular degeneration65. Other groups 
has estimated that deriving autologous iPS cell-derived NS cells takes at least 6 moths 
excluding safety testing132, the time required in the RPE cells is likely somewhat similar. 
This, paired with the cost of establishing cGMP compliant iPS lines were derivation and 
safety testing of  the cell line it most likely in the area of 165 000 €133. A staggering expense 
for the derivation of a cell line intended for only one patient. Dose delivery of the RPE sheets 
also require more intricate surgery compared to the injectable cell suspension as was the case 
with Geron’s OPCs. 
2.2.5 Goals of the Sponsor 
 
These apparent polar opposites in trial design is reflected by the different goals of the trial 
sponsor. The ambitions in the iPS cell derived RPE cell trial was rather academic and aimed 
to provide proof-of-concept rather than to develop a blockbuster therapy. Although the 
  14 
approach taken does minimize the commercial feasibility it serves the function of laying the 
foundation for which new bold projects can take shape. Since the first patient was 
transplanted in 2014 a new direction has been taken by Takahashi’s group which recently 
transplanted iPS derived RPE cells which are allogenic and HLA-matched to the recipient. 
This change vastly bolstered the possibility of creating a cell therapy reaching more 
patients.132  
2.3 AVOIDING GRAFT REJECTION IN IPS CELL DERIVED THERAPIES 
2.3.1 Autologous Grafts 
 
ATMPs are indeed a beast of its own. Unlike small molecule-based pharmaceuticals, cell 
therapies risk destruction by the immune system. As with all types of transplantation, PS cell 
derived grafts will be subjected to recognition and destruction by the host adaptive immune 
response134. The holy grail of iPS cell would be to grow any transplant from the recipients 
own cells, potentially eliminating the need for immunosuppressive therapy. Experimental 
comparisons of autologous and allogenic iPS graft transplants suggest that autologous grafts 
elicit low or none-existent adaptive immune response, displaying better graft survival even 
in the absence of immunosuppressive therapy in non-human primates135. Although, 
autologous therapies may be ideal, they are today, unfeasible on a large scale. Both the 
derivation cost, and time required for clinically relevant, GMP-compliant iPS-line is beyond 
the scope of large scale therapies136. Also, certain conditions may arise because of genetic 
traits in the patient. In these cases, autologous cells could be unsuitable since the derived 
cells would recapitulate the phenotype137.  
2.3.2 Matching of Donor and Recipient in the Stem Cell Era 
 
iPS cell technology allows for screening and donor selection on the basis of health status, 
HLA-type or blood type. The advantage of HLA-matched transplants lies in reducing 
immunogenicity in host and limiting immunosuppressive regimes. Essential for matching to 
be cost effective and practically feasible is to limit the size of the cell bank required by 
maximizing the population coverage and boosting the interchangeability in-between 
genetically distant populations. 
 
The notion of establishing an allogenic PS cell bank, HLA-matched to the population was 
first suggested by Taylor et al in 2005, even prior to the derivation of the first iPS cell lines.  
The authors suggested the derivation of 150 ES lines at random could provide HLA-A, HLA-
B and HLA-DR  match for 18,5% of the UK population138. With the dawn of iPS cell-
technology it became possible to screen for donors of the most common HLA-haplotypes 
prior to cell derivation139. Taylor et al returned with a publication in 2012 where they 
searched Bone marrow worldwide registry for potential donors for iPS cell derivation. By 
using a strategy of finding rare donors homozygous for HLA-A, HLA-B and HLA-DR, a 
strategy could be formulated and a bank of just 10 cell lines providing a match for 37,7% of 
the UK population75. Previously, Okita et all presented a strategy where 140 homozygous 
lines, selected from 160 000 screened individuals would provide match for 90,7% of the 
Japanese population140.  
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Strategies on stem cell banks have mostly been on the national level, population 
heterogeneity varies largely in-between people of different ancestries and does not align with 
national borders. Studies on the diverse American population has shown that Americans of 
European ancestry is a most homogeneous group, with a very high degree of 
interchangeability, while largely different from African Americans and Asian Americans141. 
The most common haplotype identified by Okita et al, providing a match for 8,5% of the 
Japanese population is not even present in the list of the top 236 lines presented by Taylor et 
al75. This highlights the need for creating different banks optimized for different ancestries, 
establishing common banks across national borders, and call for Haplotype sharing in-
between banks in the ever-globalizing world of today. 
 
Previous strategies have often limited their strategies to only providing a limited match to 
selected HLA alleles, contending with only partial matching. Optimal match for 
transplantations should take into account all alleles of HLA class I and HLA class II loci, 
exclusively select donors with blood group 0, preferably use female donors to avoid Y linked 
minor histocompatibility antigens136. However, actualizing even the more limited banks, 
similar to those suggested above represents an enormous effort. 
 
2.3.3 Genome Editing of HLA-Molecules 
 
Genome editing approaches such as CRISPR-Cas9 can with relative ease be applied in stem 
cells lines and target certain HLA-molecules increasing population match achieved142. One 
opportune target for gene editing is the Class II trans activator (CIITA) which is required for 
the transcription of HLA class II molecules143 or the Beta-2-Microglobulin (B2M) molecule 
required for HLA class I cell surface expression144.  
 
2.3.4 Universal Cell Lines 
 
Complete knockout of both these genes has been suggested to create non-immunogenic 
universal cell lines hypothetically tolerated in all recipients145 However, natural killer cells 
are specifically tuned to recognize the missing self-response and this strategy require the 
knock in of an exogenous HLA-E-B2M protein145. Potentially a very useful way of 
circumventing the demands of matching cells but the HLA molecules do serve important 
immune functions, important to fight infections or malignancies. The latter is especially 
troubling given the concerns of tumorgenicity of pluripotent cells.  
 
2.3.5 HLA-Retention Strategies 
 
A recent study suggested the retention of single HLA-C molecules. The retained molecule 
would deter Natural killer (NK) cells, preserve a degree of antigen presentation capability 
while minimizing the cell lines required for matching a majority of the Japanese 
population146. Essentially allowing the creation of a limited cell bank while partly conserving 
the important functions of the immune system. 
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2.3.6 Suicide Switches 
 
Introduction of inducible “suicide genes” are sometimes discussed as a failsafe to prevent 
graft overgrowth, teratoma formation or malignant transformation147 Such switches are 
placed under the control of small molecules and induce selective apoptosis of the grafted 
cells148. Nevertheless, the inclusion of such genes comes with risks of its own and are 
delivered by adeno-associated virus or integrating viral vector which will require additional 
regulatory oversight132. 
 
Genome editing approaches are capable of improving cell therapies but does come with 
concerns themselves, appropriate measures to ensure no off -target effects or other safety 
concerns will need to be answered as prescribed by the risk-based approach. Interestingly, 
the cancer therapy field may offer rare precedent were gene edited chimeric antigen receptor 
T- (CAR-T) cell therapies has advanced far enough to receive market approval149. 
 
3 PLURIPOTENT CELL DERIVED CELL THERAPIES 
3.1 DERIVATION OF CELL TYPES RELEVANT FOR REGENERATIVE 
THERAPIES 
 
Many cell types with grand potential for regenerative medicine have been successfully 
derived and tested preclinically. Including cardiomyocytes for myocardial infarction150 , RPE 
cells for macular degeneration151, ß-cells in insulin dependent diabetes152, dopaminergic 
neurons for Parkinson’s disease134, neural stem (NS) cells 153and neuroepithelial stem (NES) 
cells154 for SCI (Figure 4). 
 
 
Figure 4. From dermal biopsy to iPS cells and further on to differentiated disease relevant cell types. Cell culture 
require advanced cell laborites and highly skilled labor. Developing efficient freezing thawing protocol, means cells could 
be supplied to clinics in cryovials, thawed at convince in the operating theater and injected with minimal manipulation. The 
dermal biopsy donor can be the same as the recipient of the cell therapy as is the case in autologous cell therapy, which 
results in an optimal immunological match. Alternatively, the donor can be allogenic which enables the derivation of large-
scale cell therapy batches. Adapted from Uhlin, Marin Navarro et al, 20172. 
 
 
 
 
   17 
3.1.1 Differentiating Pluripotent Stem Cells into Disease Relevant Cell Types 
of the Central Nervous System (CNS) 
 
Efficient protocols for the neural induction of PS cells were reported over a decade ago and 
enabled the directed differentiation into disease relevant neural cell types155. iPS cells can be 
terminally differentiated to post mitotic neurons or perhaps more promising captured along 
the path of differentiation as immature, proliferating neural progenitor cells. Grafting of 
immature progenitor have shown to improve integration while retaining the capacity to 
proliferate and differentiate after transplant156. The capture of several different types of 
expandable neural progenitor cells with different temporal and spatial properties has been 
reported upon neural induction of PS cells157.  
3.1.2 Pluripotent Cell Derived Neuroepithelial Stem Cells: a Candidate for 
Repair of the CNS 
 
NES cells are a type of expandable multipotent neural stem cell type capable of 
differentiating into astrocytes158, oligodendrocytes and neurons159. NES cells can either be 
derived from pluripotent cells159 or from fetal hindbrain corresponding to gestational week 
5-7 week160.  
 
The trilineage differentiation potential, high proliferative capacity and the ability to integrate 
into the mammalian CNS makes NES cells of interest for cell therapy of the CNS157. NES 
cells are primary neurogenic and differentiate at ratios of about 90% to TUJ1 positive 
neuoranal cells and 10% giving rise to glia159.  Preclinical investigation of NES has so far 
focused on SCI where grafted animals have displayed cell integration, differentiation and 
some degree of functional recovery154, 161. NES cells can also serve as intermediate in the 
derivation of astrocytes158 or dopaminergic neurons which have potential uses in regenerative 
medicine162.     
 
A similar cell type, neural stem (NS) cells can be derived from later developmental origin 
around gestational week 8. NS cells exhibit a more gliogenic differentiation profile163 and 
differentiate at a ratio of about 50%-50% to neurons and glia164. Elegant studies have 
developed well characterized, cryopreserved cell therapy from fetal NS cells which entered 
clinical trials for amyotrophic lateral sclerosis in 2012165. The proof of safety from the 
amyotrophic lateral sclerosis trials allowed the same fetal derived NS cell line to be used in 
clinical Phase I trials for SCI in 2016. Four patients were grafted with cryopreserved NS cell 
doses with no serious adverse events reported and with some degree of functional recovery 
in two of four patients166. This provides another example of an ATMP with the potential of 
treating several indications were the safety dossier can be used in support of new applications.  
 
The fetal origin of these cells comes with many ethical issues and are inevitable a limited 
resource. Nonetheless, fetal cells have once again a come to pioneer cell therapies 
developments and do so because they circumvent the safety concerns associated with PS 
cells. Another reason for fetal cell grafts predating the use of pluripotent derived cells is the 
time required to develop new therapies. When the fetal NS cell line used in the trial was 
derived in 1996 it preceded the derivation of the first human ES cell lines and the first human 
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iPS cells by more than a decade. These advances made by fetal cell grafts serve as excellent 
proof of concept and pluripotent derived NS cells have now been approved for clinical trials 
in Japan132. 
 
Human iPS derived NES cells has been shown to have a comparable therapeutic potential to 
that of fetal spinal cord NS in mice154. Recent unpublished data indicate that NES cells have 
improved preclinical effect over NS cells in SCI associated traumatic syringomyelia167. NES 
cells also grow faster, with doubling time of 24-30 hours159 compared to 2-3 days for NS-
cells163, a useful characteristic for the large scale derivation of cell therapy doses.   
3.2 FUTURE APPLICATIONS 
 
It is important to keep in mind the tremendous progress in the field in the decade since first 
discovery when considering the future. What we deem unfeasible today many well be reality 
in a few years. The pace of developments during this PhD project has been extraordinary. An 
open mindset and innovative approach will be essential to navigate in this environment.  
 
It is encouraging to see the first clinical trials involving PS cells reporting no serious adverse 
events, and to see the first patients receiving therapies derived from iPS cells. It remains 
important to remember that this initial success can rapidly be lost if negative safety 
indications appear. The field of gene therapy is often exemplified, which was set back several 
years because of the emergence adverse events168. Proceeding with caution may prove the 
fastest way forward. 
 
As therapies are beginning to move past phase I and phase II clinical trials, the scale of 
manufacture will move from a flexible scientific scale to an industrial scale. With the scale 
increase and the implementation of automation, it is likely that costs of goods can radically 
be decreased in the near future. The technology supporting the scale up from small manual 
culture vessels to massive bioreactors has already been demonstrated with PS cells growing 
either in suspension or on microcarriers169. Rough estimates on the requirements of 
commercial manufacture puts the need of around 1011-1014 cells per year of average products 
which would equate the annual output of one 200 - 2000 liter bioreactor170. 
 
The New York Stem Cell foundation reported the development of a modular robotic platform 
capable of deriving research grade iPS cells from dermal biopsies. The platform was also 
capable of some basic characterization, with minimal manual intervention. Not only a 
promising alternative to manual derivation because of cost reasons, it was also validated that 
the lines produced displayed less variation compared to manually manufactured lines171. The 
automated system was reported to reduce reagent cost 5-6-fold171. Reprogramming by 
microfluidic chips on a microscale has reported successful reprogramming with a 100-fold 
reagents saving compared to standard 6 well reprogramming. Such microfluidic chips 
enabled 32 parallel reprogramming’s simultaneously in an automated fashion172. 
 
Although autologous cells may be unfeasible for widespread use today, it might not be so in 
the future. Just like high throughput screening revolutionized drug testing we may soon enter 
a future where high throughput cell derivation dominates. Robotics also increase the distance 
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of humans from cultures, humans often being a source of infectious organisms threatening 
cultures. Other benefits include robots being more consistent and can implement automatic 
feeding regimes based on sensors reading, changing culture components when needed rather 
than on predetermined intervals169.  
 
To conclude, iPS cells has the potential revolutionize medicine and developments in the last 
decade has went from discovery up to the threshold of in human applications. Much work 
remains to be done especially with regards to the legislative development and harmonization. 
Deriving the PS cell is part of the process. Equal considerations must be endowed the 
development of the specialized cell grafts transplanted.  
 
When can we expect to see cell therapies available to the public? The first iPS cell derived 
therapy product to conclude phase I trial was an MSC therapy in Graft vs. host disease, 
showing no serious adverse events and provided indications of efficacy67, 173 Estimates 
suggest PS cell derived therapies for macular degeneration within 2-5 years, diabetes is 
currently in phase I/II and will take longer, heart disease is in Phase I. SCI around 5 years. 
For the first iPS cell applications in eye disease is pioneering71 but trials have been approved 
for heart failure, Parkinson’s disease, SCI and are scheduled to commence imminently132.  
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Aims of this thesis 
 
The overall aim was to investigate the potential of iPS cells to be used in regenerative 
medicine. 
 
A few key projects were identified 
 
• Developing clinically relevant, xeno-free and defined protocols for the derivation of 
iPS cells 
• Establish a process for the cGMP compliant manufacture of iPS cells 
• Explore the feasibility of a HLA-mathed iPS cell bank of clinically relevant cells 
matched to the majority of the population 
• Develop clinically relevant protocol for the neural induction and capture of NES cells 
derived from iPS cells 
• Examine the potential of using NES cells to develop an ATMP for Spinal cord injury 
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4 RESULTS AND DISCUSSION 
 
The main focus of this project was to derive clinically relevant iPS cells. By our definition, 
this included: elimination of all animal components, using only defined-reagents, and 
reprogramming by a non-integrating footprint-free reprogramming system. Once a robust 
clinically relevant process had been developed, spanning from biopsy collection to iPS cell 
cryopreservation, GMP compliant manufacture would be attempted.  
 
There is no clinical utility of iPS cells alone, therefore it was decided to investigate the 
therapeutic potential of NES cells in SCI. The NES cell derivation protocol should preferably 
also conform to our definition of clinical relevance and if possible be derived using clinically 
relevant iPS cells if these could be developed.  
 
To avoid investing resources into the development functional but commercially unviable 
ATMP, we decided to take a backwards approach and factor in the possibility of 
characterization, scale up, cost of goods in the early studies of our ATMP. As a part of this 
effort we also decided to investigate alternatives to using patient specific iPS cell lines and 
cryopreservation of cell therapy doses. 
 
Paper I outlines the derivation of two research grade iPS cell lines from skin biopsies 
intended for the use as controls in disease modeling projects. In this paper we use a method 
we developed to reprogram fibroblasts by non-integrating sendai viral vector which were 
maintained as iPS cells in a fully xeno-free and defined culture system. Paper II further 
sough to define and describe our process in minute detail. This was essential for the upcoming 
technology transfer to the GMP facility and the authoring of standard operating procedures 
required for the GMP compliant manufacturing process.  
 
Fibroblast derivation was still performed using fetal bovine serum and non-recombinant 
enzymes in the treatment of the dermal biopsy. To derive clinically relevant cells by our 
definition we sought to fully eliminate xenogeneic and undefined products from all steps of 
our process. The developed method was with the exception of the biopsy preparation and 
fibroblast culture suitable. To find an alternative to media containing FBS in the culture of 
fibroblast we tested a series of commercially available media formulations. We were made 
aware that culturing fibroblasts is permissive as long as the primary culture has been 
established with serum but found the removal of serum in the early process yielded few cells 
with very limited proliferation. We set out to enhance the fibroblasts yield from our biopsy 
preparation by improving both conditions and including additional factors which improved 
the outgrowth from biopsies in a fully recombinant and defined method. We had also begun 
testing of mRNA mediated reprogramming in the laboratory, a method ideal for derivation 
of cells for clinical applications, however complicated to master as the mRNAs give rise to 
strong innate immune response in the reprogrammed cells. 
 
To facilitate the future regulatory approval of our GMP manufactured cell lines, we were 
required to scrutinize all reagents used in our process and tested alternative reagents were 
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necessary. Consultations with the Swedish medical products agency proved an invaluable 
resource to develop a mutual understanding for the requirements for eventual approval.  
For manuscript III, we had built on the previous iPS expertise in the previous papers and 
developed a similarly robust protocol using mRNA reprogramming and only clinically 
suitable reagents. Several clinically relevant lines were derived by this method to ensure the 
robustness of the method and to determine the process in detail before we could attempt to 
transfer our method to the GMP manufacturing facility. 
 
Extensive documentations was authored and the method adapted to GMP before manufacture 
could commence resulting in the cGMP compliant iPS cell line KICRi-001-A also known as 
clone #10.  
 
Manuscript V embodied what been learned along the project when it came to the 
considerations for developing an ATMP. A backwards approach was taken with the focus on 
creating a cell therapy product which could be scaled, characterized at a minimal cost of 
goods. Important for future regulatory approval was to develop a meticulous characterization 
program that could be performed on each individual batch rather than on the cell lines. Such 
characterization would require some form of preservation strategy since the quality controls 
required would take far longer than shelf-life of live dissociated cells. Considerable effort 
was spent developing a cryopreservation regime of NES cell therapy doses to develop an off-
the-shelf therapy which could be injected directly without the need of culturing cells “in 
clinic”. Cryopreservation is also important in keeping cost of goods to a minimum, since 
large banks of doses can be manufactured, stored and distributed.  
 
Developing ATMPs is very costly and depending on autologous cell source was not consider 
a feasible alternative. Considering either a non-matched allogenic or a therapy with HLA-
matched cell lines discussed in Manuscript IV. We judged the previous strategies presented 
was unfeasible, as to many lines were required. First, we attempted to demonstrate the 
unfeasibility of this approach by estimating the population screen required to identify donors 
and the cost of realizing such a strategy. Cost and screen were factors we had found being 
insufficiently explored in previous publications. We then devise a strategy which we deemed 
viable. The use of genome editing was found to greatly reduce cost, increase population 
match and interchangeability in-between distant populations.  
 
Going forward towards the future with a vision of cryopreserved cell banks of disease 
relevant cell therapy products. Either by a one line fits all approach using universal cell lines 
or possibly by each product consisting of a dozen of HLA-retained cell lines. Such cell 
therapies could be stored in hospital pharmacies around the world and with a fairly simple 
procedure be injected to regenerate injuries. Few fields of science are likely to be as exciting 
as the upcoming decade of regenerative medicine. I consider myself fortunate to have had 
the great opportunity to partake in this exhilarating field of research.   
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